Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
49
CRSP Quote, Financials, Valuation and Earnings
Last price:
$56.78
Seasonality move
:
9.38%
Day range:
$55.21 - $56.83
52-week range:
$30.04 - $78.48
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
129.35x
P/B ratio:
2.82x
Volume:
653K
Avg. volume:
2.1M
1-year change:
38.52%
Market cap:
$5.4B
Revenue:
$37.3M
EPS (TTM):
-$5.58
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CRSP
CRISPR Therapeutics AG
|
$9M | -$1.29 | -89.16% | -180.62% | $81.33 |
|
BEAM
Beam Therapeutics, Inc.
|
$12.7M | -$1.01 | -54.98% | -2.35% | $45.93 |
|
NTLA
Intellia Therapeutics, Inc.
|
$14.1M | -$1.00 | -5.94% | -24.06% | $22.43 |
|
NVS
Novartis AG
|
$13.9B | $2.31 | 5.75% | 37.94% | $134.88 |
|
ONC
BeOne Medicines Ltd.
|
$1.4B | $0.86 | 29.38% | -70.04% | $400.06 |
|
VRTX
Vertex Pharmaceuticals, Inc.
|
$3.1B | $4.58 | 10.21% | 47.45% | $491.92 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CRSP
CRISPR Therapeutics AG
|
$56.71 | $81.33 | $5.4B | -- | $0.00 | 0% | 129.35x |
|
BEAM
Beam Therapeutics, Inc.
|
$28.15 | $45.93 | $2.9B | -- | $0.00 | 0% | 47.43x |
|
NTLA
Intellia Therapeutics, Inc.
|
$9.59 | $22.43 | $1.1B | -- | $0.00 | 0% | 17.47x |
|
NVS
Novartis AG
|
$138.88 | $134.88 | $266.5B | 18.94x | $3.99 | 2.88% | 5.03x |
|
ONC
BeOne Medicines Ltd.
|
$311.73 | $400.06 | $34.5B | 599.83x | $0.00 | 0% | 6.96x |
|
VRTX
Vertex Pharmaceuticals, Inc.
|
$462.99 | $491.92 | $117.5B | 32.63x | $0.00 | 0% | 10.22x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CRSP
CRISPR Therapeutics AG
|
9.92% | 3.188 | 3.47% | 16.13x |
|
BEAM
Beam Therapeutics, Inc.
|
13.55% | 2.089 | 6.16% | 5.89x |
|
NTLA
Intellia Therapeutics, Inc.
|
11.58% | 3.323 | 4.9% | 5.57x |
|
NVS
Novartis AG
|
41.94% | 0.086 | 12.99% | 0.58x |
|
ONC
BeOne Medicines Ltd.
|
31.57% | 0.334 | 5.05% | 2.09x |
|
VRTX
Vertex Pharmaceuticals, Inc.
|
9.58% | -0.151 | 1.84% | 1.84x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CRSP
CRISPR Therapeutics AG
|
-$60.6M | -$132.1M | -23.42% | -26.17% | -14854.78% | -$84.7M |
|
BEAM
Beam Therapeutics, Inc.
|
$4.1M | -$126.8M | -38.05% | -44.48% | -1307.6% | -$86.5M |
|
NTLA
Intellia Therapeutics, Inc.
|
$8.8M | -$111.5M | -47.33% | -54.66% | -808.86% | -$76.9M |
|
NVS
Novartis AG
|
$10.3B | $4.2B | 19.37% | 33.87% | 30.24% | $5.7B |
|
ONC
BeOne Medicines Ltd.
|
$1.2B | $163.3M | 1.43% | 1.92% | 11.55% | $355.1M |
|
VRTX
Vertex Pharmaceuticals, Inc.
|
$2.7B | $1.3B | 20.08% | 22.13% | 41.02% | $1.1B |
CRISPR Therapeutics AG vs. Competitors
-
Which has Higher Returns CRSP or BEAM?
Beam Therapeutics, Inc. has a net margin of -11973.12% compared to CRISPR Therapeutics AG's net margin of -1162.38%. CRISPR Therapeutics AG's return on equity of -26.17% beat Beam Therapeutics, Inc.'s return on equity of -44.48%.
Company Gross Margin Earnings Per Share Invested Capital CRSPCRISPR Therapeutics AG-6819.57% -$1.17 $2.1B BEAMBeam Therapeutics, Inc.42.67% -$1.10 $1.1B -
What do Analysts Say About CRSP or BEAM?
CRISPR Therapeutics AG has a consensus price target of $81.33, signalling upside risk potential of 43.42%. On the other hand Beam Therapeutics, Inc. has an analysts' consensus of $45.93 which suggests that it could grow by 65.39%. Given that Beam Therapeutics, Inc. has higher upside potential than CRISPR Therapeutics AG, analysts believe Beam Therapeutics, Inc. is more attractive than CRISPR Therapeutics AG.
Company Buy Ratings Hold Ratings Sell Ratings CRSPCRISPR Therapeutics AG12 10 1 BEAMBeam Therapeutics, Inc.13 2 0 -
Is CRSP or BEAM More Risky?
CRISPR Therapeutics AG has a beta of 1.738, which suggesting that the stock is 73.75% more volatile than S&P 500. In comparison Beam Therapeutics, Inc. has a beta of 2.213, suggesting its more volatile than the S&P 500 by 121.346%.
-
Which is a Better Dividend Stock CRSP or BEAM?
CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Beam Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. Beam Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRSP or BEAM?
CRISPR Therapeutics AG quarterly revenues are $889K, which are smaller than Beam Therapeutics, Inc. quarterly revenues of $9.7M. CRISPR Therapeutics AG's net income of -$106.4M is higher than Beam Therapeutics, Inc.'s net income of -$112.7M. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while Beam Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is 129.35x versus 47.43x for Beam Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRSPCRISPR Therapeutics AG129.35x -- $889K -$106.4M BEAMBeam Therapeutics, Inc.47.43x -- $9.7M -$112.7M
-
Which has Higher Returns CRSP or NTLA?
Intellia Therapeutics, Inc. has a net margin of -11973.12% compared to CRISPR Therapeutics AG's net margin of -735.19%. CRISPR Therapeutics AG's return on equity of -26.17% beat Intellia Therapeutics, Inc.'s return on equity of -54.66%.
Company Gross Margin Earnings Per Share Invested Capital CRSPCRISPR Therapeutics AG-6819.57% -$1.17 $2.1B NTLAIntellia Therapeutics, Inc.64.19% -$0.92 $846.4M -
What do Analysts Say About CRSP or NTLA?
CRISPR Therapeutics AG has a consensus price target of $81.33, signalling upside risk potential of 43.42%. On the other hand Intellia Therapeutics, Inc. has an analysts' consensus of $22.43 which suggests that it could grow by 133.91%. Given that Intellia Therapeutics, Inc. has higher upside potential than CRISPR Therapeutics AG, analysts believe Intellia Therapeutics, Inc. is more attractive than CRISPR Therapeutics AG.
Company Buy Ratings Hold Ratings Sell Ratings CRSPCRISPR Therapeutics AG12 10 1 NTLAIntellia Therapeutics, Inc.10 11 1 -
Is CRSP or NTLA More Risky?
CRISPR Therapeutics AG has a beta of 1.738, which suggesting that the stock is 73.75% more volatile than S&P 500. In comparison Intellia Therapeutics, Inc. has a beta of 2.133, suggesting its more volatile than the S&P 500 by 113.344%.
-
Which is a Better Dividend Stock CRSP or NTLA?
CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intellia Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. Intellia Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRSP or NTLA?
CRISPR Therapeutics AG quarterly revenues are $889K, which are smaller than Intellia Therapeutics, Inc. quarterly revenues of $13.8M. CRISPR Therapeutics AG's net income of -$106.4M is lower than Intellia Therapeutics, Inc.'s net income of -$101.3M. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while Intellia Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is 129.35x versus 17.47x for Intellia Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRSPCRISPR Therapeutics AG129.35x -- $889K -$106.4M NTLAIntellia Therapeutics, Inc.17.47x -- $13.8M -$101.3M
-
Which has Higher Returns CRSP or NVS?
Novartis AG has a net margin of -11973.12% compared to CRISPR Therapeutics AG's net margin of 28.26%. CRISPR Therapeutics AG's return on equity of -26.17% beat Novartis AG's return on equity of 33.87%.
Company Gross Margin Earnings Per Share Invested Capital CRSPCRISPR Therapeutics AG-6819.57% -$1.17 $2.1B NVSNovartis AG74.59% $2.02 $76.8B -
What do Analysts Say About CRSP or NVS?
CRISPR Therapeutics AG has a consensus price target of $81.33, signalling upside risk potential of 43.42%. On the other hand Novartis AG has an analysts' consensus of $134.88 which suggests that it could fall by -2.88%. Given that CRISPR Therapeutics AG has higher upside potential than Novartis AG, analysts believe CRISPR Therapeutics AG is more attractive than Novartis AG.
Company Buy Ratings Hold Ratings Sell Ratings CRSPCRISPR Therapeutics AG12 10 1 NVSNovartis AG1 6 2 -
Is CRSP or NVS More Risky?
CRISPR Therapeutics AG has a beta of 1.738, which suggesting that the stock is 73.75% more volatile than S&P 500. In comparison Novartis AG has a beta of 0.525, suggesting its less volatile than the S&P 500 by 47.542%.
-
Which is a Better Dividend Stock CRSP or NVS?
CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novartis AG offers a yield of 2.88% to investors and pays a quarterly dividend of $3.99 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. Novartis AG pays out 55.39% of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CRSP or NVS?
CRISPR Therapeutics AG quarterly revenues are $889K, which are smaller than Novartis AG quarterly revenues of $13.9B. CRISPR Therapeutics AG's net income of -$106.4M is lower than Novartis AG's net income of $3.9B. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while Novartis AG's PE ratio is 18.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is 129.35x versus 5.03x for Novartis AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRSPCRISPR Therapeutics AG129.35x -- $889K -$106.4M NVSNovartis AG5.03x 18.94x $13.9B $3.9B
-
Which has Higher Returns CRSP or ONC?
BeOne Medicines Ltd. has a net margin of -11973.12% compared to CRISPR Therapeutics AG's net margin of 8.84%. CRISPR Therapeutics AG's return on equity of -26.17% beat BeOne Medicines Ltd.'s return on equity of 1.92%.
Company Gross Margin Earnings Per Share Invested Capital CRSPCRISPR Therapeutics AG-6819.57% -$1.17 $2.1B ONCBeOne Medicines Ltd.83.86% $1.09 $6B -
What do Analysts Say About CRSP or ONC?
CRISPR Therapeutics AG has a consensus price target of $81.33, signalling upside risk potential of 43.42%. On the other hand BeOne Medicines Ltd. has an analysts' consensus of $400.06 which suggests that it could grow by 28.34%. Given that CRISPR Therapeutics AG has higher upside potential than BeOne Medicines Ltd., analysts believe CRISPR Therapeutics AG is more attractive than BeOne Medicines Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CRSPCRISPR Therapeutics AG12 10 1 ONCBeOne Medicines Ltd.18 1 1 -
Is CRSP or ONC More Risky?
CRISPR Therapeutics AG has a beta of 1.738, which suggesting that the stock is 73.75% more volatile than S&P 500. In comparison BeOne Medicines Ltd. has a beta of 0.452, suggesting its less volatile than the S&P 500 by 54.771%.
-
Which is a Better Dividend Stock CRSP or ONC?
CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BeOne Medicines Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. BeOne Medicines Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRSP or ONC?
CRISPR Therapeutics AG quarterly revenues are $889K, which are smaller than BeOne Medicines Ltd. quarterly revenues of $1.4B. CRISPR Therapeutics AG's net income of -$106.4M is lower than BeOne Medicines Ltd.'s net income of $125M. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while BeOne Medicines Ltd.'s PE ratio is 599.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is 129.35x versus 6.96x for BeOne Medicines Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRSPCRISPR Therapeutics AG129.35x -- $889K -$106.4M ONCBeOne Medicines Ltd.6.96x 599.83x $1.4B $125M
-
Which has Higher Returns CRSP or VRTX?
Vertex Pharmaceuticals, Inc. has a net margin of -11973.12% compared to CRISPR Therapeutics AG's net margin of 34.76%. CRISPR Therapeutics AG's return on equity of -26.17% beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.13%.
Company Gross Margin Earnings Per Share Invested Capital CRSPCRISPR Therapeutics AG-6819.57% -$1.17 $2.1B VRTXVertex Pharmaceuticals, Inc.86.69% $4.20 $19.2B -
What do Analysts Say About CRSP or VRTX?
CRISPR Therapeutics AG has a consensus price target of $81.33, signalling upside risk potential of 43.42%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $491.92 which suggests that it could grow by 6.25%. Given that CRISPR Therapeutics AG has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe CRISPR Therapeutics AG is more attractive than Vertex Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CRSPCRISPR Therapeutics AG12 10 1 VRTXVertex Pharmaceuticals, Inc.17 10 1 -
Is CRSP or VRTX More Risky?
CRISPR Therapeutics AG has a beta of 1.738, which suggesting that the stock is 73.75% more volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.249%.
-
Which is a Better Dividend Stock CRSP or VRTX?
CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRSP or VRTX?
CRISPR Therapeutics AG quarterly revenues are $889K, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.1B. CRISPR Therapeutics AG's net income of -$106.4M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.1B. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while Vertex Pharmaceuticals, Inc.'s PE ratio is 32.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is 129.35x versus 10.22x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRSPCRISPR Therapeutics AG129.35x -- $889K -$106.4M VRTXVertex Pharmaceuticals, Inc.10.22x 32.63x $3.1B $1.1B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
